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Introduction
Septins are proteins that assemble into heterooligomeric com-
plexes and form nonpolar filaments that associate with cellu-
lar membranes, actin filaments, and microtubules (Hall et al., 
2008; Saarikangas and Barral, 2011; Mostowy and Cossart, 
2012). Septins act as scaffolds for protein recruitment and as 
diffusion barriers for subcellular compartmentalization (Caud-
ron and Barral, 2009; Trimble and Grinstein, 2015). They are 
implicated in numerous biological processes, and their muta-
tion or aberrant expression has been linked to various human 
pathologies (Mostowy and Cossart, 2012; Dolat et al., 2014; 
Fung et al., 2014; Angelis and Spiliotis, 2016; Pagliuso et al., 
2016). 13 different septin genes have been identified in humans 
(SEPT1–SEPT12 and SEPT14), which can be classified into 
four groups based on the encoded protein sequence homology 
(i.e., the SEPT2 group, the SEPT3 group, the SEPT6 group, and 
the SEPT7 group; Fig. 1; Kinoshita, 2003; Weirich et al., 2008; 
Mostowy and Cossart, 2012; Fung et al., 2014). These human 
genes encode for >30 protein isoforms with tissue-specific ex-
pressions. As a result, only a subset of septins may be expressed 
in a given cell type and the composition of septin filaments may 
differ in different cells or tissues. All septins contain a central 
GTP-binding domain flanked by N- and C-terminal domains 
that vary in length and sequence between different septin groups 
(Fig. 1 a; Pan et al., 2007; Weirich et al., 2008). Structural studies 
revealed that the basic unit of septin filaments is composed of the 
combinatorial association of different septins into hexameric or 
octameric complexes (Fig. 1 b; Sirajuddin et al., 2007; Kim et al., 
2011; Sellin et al., 2011). In humans, these complexes are made 
up of SEPT7–SEPT6–SEPT2–SEPT2–SEPT6–SEPT7 and/
or SEPT9–SEPT7–SEPT6–SEPT2–SEPT2–SEPT6–SEPT7–
SEPT9 alternations, with each member of a group possibly able 
to substitute for another member of the same group. Filaments 
formed by the end-on-end assembly of these complexes can pair 
with one another and form higher-order filamentous structures, 
such as linear bundles, circular rings, or gauzes. Although the 
GTP-binding domain and part of the N- and C-terminal regions 
constitute crucial interfaces for septin–septin interactions, the 
C-terminal domain of septins, which protrudes orthogonally 
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from the filament axis, has been proposed to play a key role in 
filament stabilization, bundling, and bending and/or in interac-
tions with nonseptin molecules (Fig. 1 b; Sirajuddin et al., 2007; 
Bertin et al., 2008; de Almeida Marques et al., 2012).
Septins play essential roles during mammalian cell divi-
sion and more particularly during cytokinesis, i.e., the physical 
separation of the two daughter cells (Cauvin and Echard, 2015; 
Menon and Gaestel, 2015). Indeed, SEPT2, SEPT6, SEPT7, 
SEPT9, and SEPT11 are localized along the cleavage furrow 
or at the cytokinetic bridge, and septin depletion leads to cy-
tokinesis failures, such as delayed or unresolved abscission, 
generation of binucleated cells, or cell apoptosis (Oegema et 
al., 2000; Kouranti et al., 2006; Estey et al., 2010; Kim et al., 
2011; Founounou et al., 2013; Fung et al., 2014). In mammalian 
cells, different septins exhibit distinct roles during cytokinesis. 
Depletion of SEPT2, SEPT7, or SEPT11 leads to abnormal fur-
row constriction, revealing a role of these septins in cleavage 
furrow ingression, whereas depletion of SEPT9 strongly delays 
cell abscission (Joo et al., 2007; Estey et al., 2010).
SUMOylation is a posttranslational modification consist-
ing of the covalent addition of a small ubiquitin-like modifier 
(SUMO) polypeptide to target proteins. In humans, three func-
tional SUMO isoforms (SUMO1, SUMO2, and SUMO3) are 
encoded in the genome. They can be conjugated to distinct and 
overlapping sets of proteins and play essential roles in various 
cellular processes (Flotho and Melchior, 2013). Pioneering stud-
ies in Saccharomyces cerevisiae have shown that yeast septins 
can be modified by SUMO and that this modification plays a role 
in the disassembly of bud neck–associated septin rings during 
yeast cell division (Johnson and Blobel, 1999; Takahashi et al., 
1999). Yet, the ability of septins from other species, in particular 
humans, to be SUMOylated, as well as the role of this modifi-
cation in septin function, is unknown. Interestingly, two studies 
have identified components of the SUMOylation machinery as 
putative interactors of specific human septins, including Ubc9/
UBE2I (the E2 SUMO enzyme), PIAS3 (an E3 SUMO en-
zyme), or SUMO1 itself (Nakahira et al., 2010; Havugimana et 
al., 2012). Here, by conducting a systematic analysis of all four 
human septin groups, we unveil that human septins can be mod-
ified by SUMO and highlight a critical role for SUMO modifi-
cation of specific septins (i.e., SEPT6, SEPT7, and SEPT11) in 
septin filament bundling and cell division.
Results
Human septins from the four different 
septin groups can be modified by SUMO
To assess whether human septins can be modified by SUMO, 
we studied members of each of the four human septin groups. 
We selected SEPT2, SEPT6, and SEPT7, which together form 
a basic hexameric complex (Sirajuddin et al., 2007). We also 
selected SEPT9, which occupies a terminal position in septin 
octameric complexes (Kim et al., 2011; Sellin et al., 2011), and 
SEPT11, a septin closely related to SEPT6 with unique cellular 
functions (Fig. 1, c and d; Röseler et al., 2011).
We first addressed whether septins were able to inter-
act with Ubc9, the unique E2 enzyme of the SUMOylation 
Figure 1. Interaction between septins and the human 
SUMOylation machinery. (a) Schematic representation of 
a prototypical human septin protein (++, phosphoinositi-
de-binding polybasic region; SUE, septin unique element). 
(b) Schematic organization of typical hexameric and oct-
americ septin complexes. Dashed lines represent extensions 
formed by septin C-terminal domains. (c) Phylogenetic tree 
of human septins clustering into four different groups (aster-
isks denote septins analyzed in this study). (d) Schematic rep-
resentation of the five human septins analyzed in this study. 
(e) HeLa cells were cotransfected with HA-tagged septins and 
FLAG-tagged Ubc9. Cell lysates were subjected to immuno-
precipitation (IP) using anti-FLAG antibodies, and coimmuno-
precipitation of septins was assayed by immunoblot analysis 
using anti-HA, anti-FLAG, and anti-Ubc9 antibodies (S2, 
SEPT2; S6, SEPT6; S7, SEPT7; S9, SEPT9; S11, SEPT11).
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machinery. HeLa cells were cotransfected with expression vec-
tors for FLAG-tagged Ubc9 and different HA-tagged septins 
belonging to each human septin group. SEPT2, SEPT6, SEPT9, 
and SEPT11 coimmunoprecipitated with Ubc9, demonstrating 
that human septins from three different septin groups can inter-
act with the SUMOylation machinery (Fig. 1  e). For SEPT7, 
we did not observe coimmunoprecipitation with Ubc9 in our 
experimental conditions. To further demonstrate that mam-
malian septins could be modified by SUMO, HeLa cells were 
transfected with expression vectors for HA-tagged septins and 
plasmids encoding either His6-tagged SUMO1, SUMO2, or 
nonconjugatable SUMO1ΔGG or SUMO2ΔGG mutants (i.e., 
SUMO mutants deleted for the C-terminal diglycine motif re-
quired for SUMO conjugation; Fig. S1; Flotho and Melchior, 
2013). After cell lysis in denaturing conditions, SUMOylated 
proteins (i.e., proteins covalently attached to His-tagged SUMO) 
were pulled down, and the presence of SUMOylated septins 
was assayed by immunoblotting experiments using anti-HA 
antibodies. We detected one or several bands of higher molec-
ular weight in the His pull-down fraction for each of the five 
septins tested, corresponding to SUMOylated forms of septins 
(Fig. 2 a). These SUMO-conjugated forms were observed both 
with SUMO1 and 2 and were absent with the nonconjugatable 
SUMO1ΔGG or SUMO2ΔGG mutants, indicating that septins 
from all four human septin groups can be SUMOylated by both 
SUMO1 and 2 (Fig. 2 a).
To confirm that endogenous septins are SUMO targets, 
we transfected HeLa cells with a His6-tagged SUMO1 expres-
sion vector alone and pulled down SUMOylated proteins. Using 
immunoblot analysis with antiseptin antibodies, we detected 
high–molecular weight bands corresponding to SUMOylated 
forms of endogenous SEPT7 (Fig. 2 b). These bands were not 
observed when cells were transfected with a nonconjugatable 
SUMO1ΔGG mutant (Fig. 2 b). This result indicates that en-
dogenous SEPT7 are SUMO modified in human cells. Although 
we could not detect SUMOylated forms of other septins in our 
experimental setup, recent proteomic data identified endogenous 
SEPT2, SEPT5, SEPT6, SEPT7, SEPT8, SEPT9, and SEPT10 as 
SUMO targets (Becker et al., 2013; Hendriks et al., 2015, 2017; 
Hendriks and Vertegaal, 2016). Together, these results demon-
strate that septins can be conjugated to SUMO in mammals.
SEPT7 is constitutively SUMOylated 
during the cell cycle
In yeast, the SUMOylation level of septins is regulated during 
the cell cycle with an increase in SUMOylation appearing 
Figure 2. SUMOylation of human septins. (a) HeLa 
cells were cotransfected with WT His6-SUMO1, 2, 
or nonconjugatable (ΔGG) mutants and HA-tagged 
septins. Cell lysates were then subjected to denatur-
ing His pull-down, and the presence of SUMOylated 
septins was assayed by immunoblot analysis using 
anti-HA antibodies (asterisks represent nonspecific 
binding of un-SUMOylated septins to nickel–nitri-
lotriacetic acid beads). Input fractions are shown as 
controls. (b) Immunoblot analysis, using anti-SEPT7 
antibodies, of His pull-down proteins from HeLa cells 
transfected with WT or nonconjugatable (ΔGG) 
His6-SUMO1. Input fractions are shown as control. 
(c) Immunoblot analysis of His pull-down proteins 
from synchronized HeLa cells transfected with WT 
His6-SUMO1. Anti-RanGAP1 antibodies were used 
to monitor pull-down of SUMOylated proteins. Anti- 
phosphorylated histone H3 antibodies (phos-H3) 
were used to control cell cycle synchronization.
JCB • Volume 216 • NumBer 12 • 20174044
during mitosis before anaphase onset and disappearing at cy-
tokinesis (Johnson and Blobel, 1999). To assess whether SU-
MOylation of septins is cell cycle dependent in human cells, 
we transfected HeLa cells with His6-tagged SUMO1 expres-
sion vector and synchronized them using a double thymidine 
block procedure. Cells were lysed at different time points after 
the release from the second thymidine block to cover differ-
ent stages of the cell cycle (i.e., S phase, G1 phase, mitosis, 
early cytokinesis, and late cytokinesis). SUMOylated proteins 
were then pulled down, and the SUMOylation level of endoge-
nous SEPT7 was analyzed by immunoblotting experiments. In 
contrast to the situation described in yeast, we did not observe 
abrupt changes in the SUMOylation level of SEPT7 in human 
cells, indicating that SEPT7 is likely constitutively SUMO- 
ylated throughout the cell cycle (Fig. 2 c).
Identification of SUMO sites from human 
septins in their N- or C-terminal domains
To assess the role of septin SUMOylation, it was important 
to first map the sites of SUMO conjugation in septins. We 
thus generated 10 different K to R mutants in SEPT2, SEPT6, 
SEPT7, SEPT9, and SEPT11 (Fig.  3  a). HeLa cells were 
transfected with expression vectors for these septin mutants 
and His6-SUMO1, and the presence of SUMOylated forms 
of septins was assessed. In the case of SEPT11, mutation of 
the K315 lysine of the C-terminal domain led to the loss of 
one of the two SEPT11 SUMOylated forms, strongly suggest-
ing that K315 constitutes a SUMOylation site for SEPT11 
(Fig.  3  b). Interestingly, we found that the homologous ly-
sine in SEPT6, belonging to the same septin group, is also a 
SUMOylation site (K316; Fig.  3  b). Individual mutations of 
other SEPT11 lysine residues into arginine did not allow us 
to identify the other SEPT11 SUMO sites, probably because 
of redundancy between different potential SUMO sites, as 
classically observed for other SUMO targets. To obtain a non- 
SUMOylatable mutant of SEPT11, we derived two SEPT11 
mutants in which either all the lysines of the N-terminal and 
GTP-binding domain (SEPT11 KRn+m) or all the lysines of 
the C-terminal domain (SEPT11 KRc mutant) were changed 
to arginines (Fig.  3  a). Strikingly, no SUMOylated forms 
could be observed with the SEPT11 KRc mutant, whereas 
the SEPT11 KRn+m mutant has a SUMOylation pattern sim-
ilar to WT SEPT11. Together, these results indicate that the 
two major SUMO sites of SEPT11 are localized in the C-ter-
minal domain (Fig. 3 b).
For SEPT6 and SEPT7, we similarly derived mutants 
in which all the C-terminal lysines were replaced by argi-
nines (SEPT6 and SEPT7 KRc mutants; Fig. 3 a). As for the 
SEPT11 KRc mutant, SUMOylation of these septin mutants 
was abolished (Fig.  3  b), indicating that the major SUMO 
sites for SEPT6 and SEPT7 are all located in their C-terminal 
domains. These observations fit well with the structural data 
showing that the C-terminal domains of these septins protrude 
from the septin filament core (Sirajuddin et al., 2007) and are 
thus accessible to the SUMOylation machinery. For SEPT9 
(i.e., SEPT9_i1 isoform), which, in contrast to the previously 
tested septins, possessed a small C-terminal domain and a 
long N-terminal domain (Fig.  1), a mutation of the unique 
lysine of the SEPT9 C-terminal domain K579 did not affect 
its SUMOylation profile (Fig.  3  b). In contrast, mutation of 
all the lysines from the SEPT9 N-terminal domain impaired 
its SUMOylation, suggesting that SEPT9 SUMO sites lie in 
the N-terminal domain of this septin (Fig.  3). Finally, in the 
case of SEPT2, mutations of the three lysines of its C-termi-
nal domain only partially reduced the number of SUMOylated 
bands, whereas mutation in the unique lysine of its N-terminal 
domain had no effect on SEPT2 SUMOylation pattern (Fig. 3). 
This suggests that at least one SUMO site lies in the SEPT2 
C-terminal domain but that other SUMO sites lie in the central 
domain, although we were unable to generate a non-SUMO- 
ylatable variant for this septin. The role of SEPT2 SUMOyla-
tion could thus not be assessed.
Figure 3. Mapping of human septin SUMOy-
lation sites. (a) Schematic representation of HA-
tagged WT and mutant SEPT2, SEPT6, SEPT7, 
SEPT9, and SEPT11. Black arrowheads indi-
cate K to R mutations (KRn, K to R mutant in all 
N-terminal lysines; KRn+m, K to R mutant in all 
N-terminal and central domain lysines; KRc, K 
to R mutant in all C-terminal lysines). (b) HeLa 
cells were cotransfected with WT His6-SUMO1 
and WT or mutant HA-tagged septins. Cell ly-
sates were then subjected to denaturing His pull-
down, and the presence of SUMOylated septins 
was assayed using anti-HA antibodies. Input 
fractions are shown as controls.
role of Sumoylation in human septin function • ribet et al. 4045
SUMOylation of SEPT7 and SEPT11 
is critical for high-order septin filament 
organization and dynamics
We next used non-SUMOylatable variants of septins to char-
acterize the putative role of SUMO in septin functions. We 
first investigated whether SUMO was involved in septin fila-
ment assembly. We analyzed by immunofluorescence HeLa 
cells transfected with expression vectors for different versions 
of HA-tagged septins (Fig.  4  a). For SEPT9, no morpholog-
ical differences could be observed between filaments formed 
by WT or non-SUMOylatable septin variants. Strikingly, for 
SEPT6, SEPT7, and SEPT11, the expression of non-SUMO- 
ylatable variants led to the formation of aberrant septin filament 
assemblies (Fig. 4, a and b). These assemblies, hereafter called 
aberrant bundles, appeared as thick and intense and clearly dif-
fer from septin assemblies formed by WT septins (Fig. 4, a and 
c). Colabeling with endogenous septins indicates that these ab-
errant septin bundles incorporate other cellular septins, such as 
SEPT2 or SEPT9 (Fig. 4 a, Fig. S2, and Fig. S3).
To assess whether SUMOylation of septins modify septin–
septin interactions, we transfected HeLa cells with expression 
vectors for HA-tagged septins. Using immunoprecipitation ex-
periments, we observed that endogenous SEPT2 and SEPT11 
coimmunoprecipitate with both WT and non-SUMOylatable 
HA-tagged SEPT7 (Fig. S4 a). This indicates that a lack of SU-
MOylation does not inhibit SEPT7’s ability to form complexes 
with septins from other septin groups. Of note, we observed 
that the level of coimmunoprecipitated endogenous septins was 
higher with non-SUMOylatable SEPT7 than with WT, which 
may indicate stronger interactions (Fig. S4 a). We similarly ob-
served that endogenous SEPT2 and SEPT7 coimmunoprecipi-
tated with both WT and non-SUMOylatable SEPT11. Again, the 
level of coimmunoprecipitated endogenous septins was higher 
with non-SUMOylatable SEPT11 than with WT (Fig. S4 a).
Intimate relationships between septin and actin dynamics 
have been described for a range of cellular processes (Mostowy 
and Cossart, 2012). By performing the colabeling of septins 
with actin, we observed a complete lack of colocalization be-
tween aberrant bundles formed by non-SUMOylatable SEPT6, 
SEPT7, or SEPT11 and actin, whereas WT septin assemblies 
partially colocalized with actin filaments (Fig. S2 and Fig. S3).
Altogether, and given that expression of non-SUMOylat-
able SEPT6, SEPT7, or SEPT11 variants does not alter endog-
enous septin protein levels (Fig. S4 b), our results suggest that 
SUMOylation of these septins is strictly required for the correct 
organization of septin filaments in HeLa cells. We confirmed 
these observations in another epithelial cell line, i.e., U-2 OS 
cells. Expression of non-SUMOylatable septin mutants in U-2 
OS cells also led to the formation of aberrant septin bundles that 
colocalized with endogenous septins, but not with actin (Fig. 
S5, a and b). This indicates that SUMOylation plays a role in 
septin filament organization in several human cell types.
To monitor whether SUMOylation of septins was involved 
in septin filament dynamics, we performed FRAP experiments 
Figure 4. Non-SUMOylatable septin variants form aberrant bundles. (a) Fluorescent light microscopy images of HeLa cells transfected with HA-tagged 
WT or non-SUMOylatable SEPT7 and SEPT11 variants. Cells were stained for HA-tagged septins (anti-HA antibodies, green) and endogenous septins 
(anti-SEPT2 antibodies, red). (b) Percentage of HeLa cells displaying aberrant septin bundles after transfection with WT or mutant SEPT6, SEPT7, SEPT9, or 
SEPT11 (mean from three independent experiments; error bars, SD; ***, P < 0.001). (c) Examples of aberrant septin bundles observed in cells expressing 
non-SUMOylatable SEPT6, SEPT7, and SEPT11 variants. Cells were stained for HA-tagged septins (anti-HA antibodies). Bars, 5 µm.
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on HeLa cells expressing GFP-tagged septins. HeLa cells 
were transfected with WT or non-SUMOylatable GFP-tagged 
SEPT11. GFP-labeled filaments were irradiated with a laser 
beam to irreversibly photobleach GFP. Fluorescence recov-
ery in the bleached area was then monitored to evaluate the 
exchange of nonbleached septin monomers in preformed fil-
aments (Fig.  5  a). Whereas septin assemblies formed by WT 
SEPT11 displayed rapid recovery of fluorescence (50% of flu-
orescence intensity was recovered in <2.5 min), only very little 
recovery was observed in the case of aberrant bundles formed 
by non-SUMOylatable septins (<5% of the initial fluorescence 
intensity was recovered 6 min after bleaching; Fig. 5 b). This 
indicates that the rate of septin exchange within these aberrant 
bundles is strongly reduced and that the corresponding septin 
structures are poorly dynamic compared with WT ones.
Together, these results show that the absence of SUMO- 
ylation leads to the formation of septin bundles with aberrant 
morphology and dynamics and thus imply that SUMOylation is 
essential for normal septin filament organization.
Absence of SEPT6, SEPT7, and SEPT11 
SUMOylation leads to cytokinesis defects
To get further insights into the role of SUMOylation in septin 
functions, we assessed whether expression of non-SUMOylat-
able septin variants leads to cell division defects. Indeed, septins 
were originally characterized for their essential role in cell di-
vision in yeast and then in metazoans, and septin depletion has 
been reported to induce cytokinesis defects classically resulting 
in the generation of multinucleated cells (Hartwell et al., 1970; 
Neufeld and Rubin, 1994; Kinoshita et al., 1997; Nagata et al., 
2003; Kremer et al., 2005; Spiliotis et al., 2005; Estey et al., 
2010; Chesneau et al., 2012; El Amine et al., 2013). Here, we 
transfected HeLa cells with expression vectors for HA-tagged 
septins and quantified by immunofluorescence analysis, 72  h 
after transfection, the frequency of multinucleated cells as a re-
porter of cytokinesis defects. We observed that the frequency 
of multinucleated cells was not changed for cells expressing 
the SEPT9 non-SUMOylatable variant compared with WT 
SEPT9 (Fig.  6  a). In contrast, expression of SEPT6, SEPT7, 
and SEPT11 KRc mutants increased the level of multinucleated 
cells compared with cells expressing WT septins, suggesting 
that SUMOylation of these septins is required for the correct 
completion of cell division (Fig. 6 a). Of note, SEPT6 K316R 
and SEPT11 K315R mutants, which still exhibit partial SUMO- 
ylation (Fig. 3), did not show any defect in cytokinesis com-
pared with SEPT6 KRc and SEPT11 KRc mutants, respectively.
To confirm that a lack of SUMOylation of SEPT7 or 
SEPT11 was responsible for the observed defects in septin bun-
dle formation and in cell division, we generated expression vec-
tors for constitutively SUMOylated septins by fusing SUMO to 
the C-terminal domain of WT and non-SUMOylatable septin 
variants (SEPT7 WTSUMO, SEPT7 KRcSUMO, SEPT11 WTSUMO, 
and SEPT11 KRcSUMO; Fig. 6 b). This strategy, which mimics an 
irreversible covalent linkage of SUMO to a given target, has clas-
sically been used to analyze the function of ubiquitin-like mod-
ifications (Carter and Vousden, 2008; Choi et al., 2011; Ferreira 
et al., 2011). By transfecting HeLa cells with these expression 
vectors, we observed that constitutively SUMOylated SEPT7 
and SEPT11 assembled into filaments that colocalize with en-
dogenous SEPT2 and actin (Fig. 6 c). Remarkably, SEPT7 KRc-
SUMO and SEPT11 KRcSUMO variants, in contrast to SEPT7 KRc 
and SEPT11 KRc mutants, did not form aberrant septin bundles 
(Fig. S5 d). This result indicates that the C-terminal fusion of 
SUMO allows a functional complementation of the correspond-
ing KRc mutant and confirms that the observed defects in the 
formation of septin bundles observed with SEPT7 and SEPT11 
KRc variants are caused by a lack of SUMOylation. In paral-
lel, we quantified the frequency of multinucleated cells in HeLa 
cells expressing these septins fused to SUMO. Expression of 
SEPT7 KRcSUMO and SEPT11 KRcSUMO variants, in contrast to 
SEPT7 KRc and SEPT11 KRc, did not show cytokinesis de-
fects, highlighting that the C-terminal fusion of SUMO restores 
the phenotype of non-SUMOylatable septin variants (Fig. 6 d). 
Interestingly, this suggests that the exact location of SUMO is 
not critical for SEPT7 and SEPT11. We finally assayed whether 
septin KRcSUMO1 variants could complement cell division defects 
induced by KRc mutants using cotransfection experiments. For 
this, HeLa cells were cotransfected with expression vectors for 
SEPT KRc variants together with expression vectors for SEPT 
WT, KRc, WTSUMO1, or KRcSUMO1 variants. For SEPT7, we ob-
served that cotransfection of SEPT7 WT with SEPT7 KRc can 
partially restore the cell division defects induced by SEPT7 KRc 
alone (Fig. S5 e). We observed a similar complementation when 
SEPT7 KRcSUMO1 was cotransfected with SEPT7 KRc, indicat-
ing that constitutively SUMOylated SEPT7 can functionally re-
store defects induced by SEPT7 KRc (Fig. S5 e). Similar results 
Figure 5. Role of SUMOylation in septin dynamics. HeLa cells were transfected with GFP-tagged WT or non-SUMOylatable (KRc) SEPT11, and GFP-labeled 
septin filaments were subjected to FRAP. (a) Representative images of fluorescence recovery for WT and KRc SEPT11 filaments. Boxes indicate bleached 
regions. Bars, 5 µm. (b) Kinetics of fluorescence recovery (mean from six to seven independent fields of one representative experiment; error bars, SD).
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were obtained for SEPT11 (Fig. S5 e). To extend our findings, 
we performed these experiments in U-2 OS cells. We observed 
similar cytokinesis defects for SEPT7 and SEPT11 non-SUMO- 
ylatable mutants that were not observed with the corresponding 
constitutively SUMOylated variants (Fig. S5 c). This indicates 
that SUMOylation of these septins plays a role in cell division in 
several human cell types.
Lack of septin SUMOylation interferes with 
late steps of cytokinesis
Cytokinesis is a multistep process allowing the physical sep-
aration of the daughter cells. It starts with the formation of an 
actin/myosin-based contractile ring that drives the ingression of 
the cleavage furrow. Once the ring has contracted, the formed 
intercellular bridge between the two daughter cells matures and 
is finally cut through a process called abscission.
To identify at which step of the cytokinesis process septin 
SUMOylation is involved, HeLa cells were cotransfected with 
expression vectors for SEPT7 and for GFP. Cell division of 
transfected cells (i.e., GFP-positive cells) was followed by 
time-lapse microscopy for 48 h (Fig. 7 a). We did not observe 
significant differences in times required for cleavage furrow 
formation between cells expressing WT or non-SUMOylatable 
SEPT7 variants (Fig.  7  b). Interestingly, for cells expressing 
SEPT7 KRc, we always observed cleavage furrow ingression, 
but in cells failing in cell division, this furrow loosened, lead-
ing to a refusion of the two daughter cells and to the generation 
of binucleated cells (Fig.  7  a). These refusion events occurred 
on average 249 ± 90 min after cell rounding and were detected 
significantly more frequently in cells expressing non-SUMO- 
ylatable SEPT7 variants than in cells transfected with control 
plasmids or expressing WT SEPT7 or SEPT7 fused to SUMO 
(Fig. 7 b). For the remaining cells, no differences were observed 
in times required for intercellular bridge abscission or between 
two cell division events (Fig. 7 b). Thus, a lack of septin SUMO- 
ylation is unlikely to affect the cell cycle, nor does it induce a 
delay in cleavage furrow formation or cell–cell separation. Our 
results show that the presence of non-SUMOylatable septins leads 
to late cytokinetic defects, characterized by intercellular bridge 
instability after furrow ingression. Of note, the functional inacti-
vation of most septins leads to a similar postfurrowing regression 
of the intercellular bridge and the formation of binucleated cells 
(Kinoshita et al., 1997; Kouranti et al., 2006; Estey et al., 2010).
As SEPT7 KRc and SEPT11 KRc variants lead to the for-
mation of aberrant septin bundles, we hypothesized that these 
structures could be responsible for the observed cytokinesis 
defects. The presence of such bundles in intercellular bridges 
during cytokinesis may indeed mechanically hinder the abscis-
sion of the two daughter cells and destabilize the bridge. To 
test this hypothesis, we used KIF20A/Rabkinesin-6 protein as a 
marker of midbodies (Echard et al., 1998; Hill et al., 2000; Fon-
tijn et al., 2001) and analyzed by immunofluorescence whether 
aberrant filaments formed by non-SUMOylatable septin vari-
ants localize at cell bridges during cytokinesis (Fig. 8 a). We 
Figure 6. Role of septin SUMOylation in cell division. (a) Percentage of HeLa cells exhibiting multinucleation after transfection with a control plasmid 
(pCDNA.3; CTRL) or expression vectors for WT or mutant septins (mean from three to five independent experiments). (b) Schematic representation of 
SUMOylated HA-tagged septin (top) or septin C-terminally fused to SUMO (bottom). (c) Fluorescent light microscopy images of septin filaments formed 
by WT or non-SUMOylatable SEPT7 and SEPT11 mutants C-terminally fused to SUMO in HeLa cells. Cells were stained for HA-tagged septins (anti-HA 
antibodies, green), endogenous SEPT2 (anti-SEPT2 antibodies, red), and actin (phalloidin, magenta). Bars, 5 µm. (d) Percentage of HeLa cells exhibiting 
multinucleation after transfection with WT, non-SUMOylatable, or constitutively SUMOylated SEPT7 and SEPT11 (mean from three to six independent 
experiments). Error bars, SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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observed that all SEPT7 and SEPT11 variants localized to the 
intercellular bridge, indicating that cell division defects are not 
caused by mislocalization of septins out of cell–cell bridges 
(Fig. 8 b). Interestingly, 15.0 ± 5.3% of the cells in cytokinesis 
that expressed non-SUMOylatable SEPT7 displayed long (>5 
µm) and thick (>1 µm) bundles of septins within the intercellu-
lar bridge (as shown in Fig. 8 a), which matches with the 14.7 
± 3.5% of cells that became binucleated as measured by time-
lapse microscopy (Fig. 7 b). In contrast, long and thick bundles 
of septin filaments were not observed in cells expressing WT or 
KRcSUMO SEPT7 variants (Fig. 8 b), which displayed low levels 
of binucleated cells. In the case of SEPT11, quantification fur-
ther revealed that 9.3 ± 2.3% of the cells in cytokinesis that ex-
pressed non-SUMOylatable SEPT11 displayed long and thick 
bundles of septins within the intercellular bridge, which again 
matches with the 8.4 ± 1.9% of cells that became binucleated 
(Fig. 6 a). Altogether, these results are consistent with the idea 
that cells with long and thick septin bundles will not be able 
to maintain stable bridges and eventually become binucleated.
We conclude that SUMOylation of SEPT7 and SEPT11 
plays a pivotal role in the organization of septin filaments and 
in cell division in mammalian cells.
Discussion
Posttranslational modifications are critical modulators of com-
ponents of the cell cytoskeleton. In particular, SUMOylation 
of cytoskeletal proteins, such as actin, tubulin, or intermediate 
filaments, or of cytoskeleton architecture regulators has been pre-
viously reported (Impens et al., 2014; Hendriks and Vertegaal, 
2016). Here, we show that septins from all four human septin 
groups can be covalently modified by either SUMO1 or SUMO2. 
We provide evidence for interactions of human septins with the 
cell SUMOylation machinery, identified that at least SEPT7 can 
be SUMO modified at the endogenous level, and mapped septin 
SUMO sites in the N-terminal domain for SEPT9 or the C-termi-
nal domain for SEPT6, SEPT7, and SEPT11. Interestingly, the 
SUMO sites of yeast septins have also been identified in either 
the C-terminal domains (for Cdc11 and Shs1) or N-terminal do-
mains (for Cdc3), although these domains do not share a sequence 
homology with human septins (Johnson and Blobel, 1999). Our 
data extend the first observations of septin SUMOylation initially 
made in yeast and corroborate previous high-throughput analy- 
ses of SUMOylated proteins that identified human septins as 
genuine SUMO targets (Johnson and Blobel, 1999; Takahashi et 
al., 1999; Becker et al., 2013; Hendriks and Vertegaal, 2016). Of 
note, a very recent human SUMO proteome identified some of 
the SUMO-modified lysines in SEPT2, SEPT6, SEPT7, SEPT8, 
SEPT9, and SEPT10 (Hendriks et al., 2017). This analysis cor-
roborates our results obtained by the analysis of SUMOylation of 
septin mutants: two SUMO sites were identified in the C-terminal 
domain of SEPT6 (including K316), one SUMO site was iden-
tified in the C-terminal domain of SEPT7, and five SUMO sites 
were identified in the N-terminal domain of SEPT9. Additional 
SUMO sites were identified in SEPT6, SEPT7, and SEPT9 cen-
tral domains, but our mutagenesis analysis suggests that these do 
not constitute major SUMO sites.
Figure 7. Lack of septin SUMOylation interferes with late steps of cytokinesis. (a) Representative images from time-lapse microscopy analysis of HeLa 
cells expressing WT or non-SUMOylatable SEPT7. Images correspond to different cell division events including cell rounding, cleavage furrow ingression, 
intercellular bridge formation, and either bridge abscission (top) or bridge regression and formation of a binucleated cell (bottom). Bars, 10 µm. (b) Time-
lapse microscopy analysis of HeLa cells transfected with control plasmid (pCDNA.3; CTRL) or expression vectors for SEPT7 WT, KRc, or KRcSUMO1 variants. 
24 h after transfection, time-lapse sequences of cells were recorded every 20 min for 48 h. At least 50 transfected cells were analyzed for each condition 
in each experiment. Means ± standard errors from three independent experiments are indicated. *, P < 0.05 compared with control condition (two-tailed 
two-sample equal-variance Student’s t test). aPercentage of cells for which cell division results in the formation of binucleated cells. bTime between cell round-
ing and furrow ingression. cTime between cell rounding and intercellular bridge abscission. dTime between two cell-rounding events. n.a., not applicable.
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By analyzing the phenotype of different cell lines express-
ing non-SUMOylatable septin variants, we demonstrate that 
septin SUMOylation plays a critical role in the organization of 
septin filaments. Specifically, SUMOylation of a set of septins 
prevents their bundling into aberrant structures. We show that a 
lack of SUMOylation in SEPT7 and SEPT11 does not inhibit 
canonical septin complex formation. In addition, assembly of 
septin filaments can be observed with C-terminally truncated 
septins (in particular with SEPT6 and SEPT7; Sirajuddin et al., 
2007). Finally, we could not identify SUMO-interacting mo-
tifs (SIMs), i.e., domains mediating noncovalent interactions 
with SUMO moieties in human septins in silico (Table S1). 
Collectively, these results suggest that SUMOylation is not re-
quired for septin–septin interactions per se. Thus, we propose 
that SUMOylation of septins instead regulates interactions 
with nonseptin molecules critical for the correct assembly of 
septin higher-order structures. This fits well with the mapping 
of SUMO sites in the C-terminal domain of SEPT6, SEPT7, 
and SEPT11, which are domains known to be involved in bun-
dling and bending and/or in interactions with nonseptin mole-
cules (Sirajuddin et al., 2007; Bertin et al., 2008; de Almeida 
Marques et al., 2012). A lack of septin SUMOylation, and thus 
a lack of recruitment of these septin-interacting factors, would 
consequently lead to assembly defects and accumulation of bun-
dles with aberrant thickness and dynamics. Of note, as for the 
vast majority of other SUMO targets, the cellular level of septin 
SUMOylation is low in steady state. This may indicate that 
septins are only transiently SUMOylated (for example, during 
the bundling of different preassembled septin filaments) and/or 
that only a small fraction of septin monomers is decorated by 
SUMO in an assembled filament. Our observation that SUMO- 
ylation of SEPT6, SEPT7, and SEPT11, but not SEPT9, is crit-
ical for septin filament organization furthermore highlights the 
specific role of SUMOylation of different septins. This result 
is in agreement with previous studies suggesting that octam-
ers versus hexamers might have different roles, even within the 
same cell type (Kim et al., 2011; Sellin et al., 2011). Interest-
ingly, other posttranslational modifications have been reported 
for septins that modulate septin assembly, including phosphor-
ylation, acetylation, and ubiquitylation (Hernández-Rodríguez 
and Momany, 2012). In particular, phosphorylation of the 
C-terminal domain of the yeast Shs1 septin was recently shown 
to regulate the capacity of Shs1-containing septin complexes to 
form rings (Garcia et al., 2011). Collectively, these data suggest 
that a complex set of coordinated posttranslational modifica-
tions tightly regulates the three-dimensional architecture of the 
septin cytoskeleton. Of note, the role of septin posttranslational 
modifications has mainly been characterized in yeast, whereas 
their function in mammals remains poorly understood. In mam-
malian cells, defects in septin SUMOylation, and thus in septin 
cytoskeleton architecture, may have severe outcomes in cell 
physiology, such as defects in late cytokinetic stages, after fur-
row ingression. Interestingly, mutations of lysine residues in the 
C-terminal domain of SEPT6 and SEPT7 have been reported in 
carcinoma samples (Catalogue of Somatic Mutations in Cancer; 
Angelis and Spiliotis, 2016). Whether these mutations or other 
naturally occurring mutations affect septin SUMOylation is 
unknown. Our results thus open new avenues for better under-
standing the molecular mechanisms underlying human diseases 
in which septins have been implicated.
Materials and methods
Plasmids
References and information on plasmids are described in Table S2. 
pCDNA3-FLAG-Ubc9 plasmid encoding N-terminal FLAG-tagged 
Ubc9 was obtained by changing the tag from the pCDNA3-HA-Ubc9 
plasmid (gift from F. Melchior, Zentrum für Molekulare Biologie der 
Universität Heidelberg, Heidelberg, Germany; Bossis and Melchior, 
2006). pSG5-His6-SUMO1 and SUMO2 plasmids encoding N-termi-
nal His6-tagged mature SUMO isoforms were previously described in 
Impens et al. (2014). pSG5-His6-SUMO1ΔGG and SUMO2ΔGG plas-
mids encode SUMO isoforms in which the C-terminal diglycine motif 
was deleted. Plasmids encoding human septins with a C-terminal HA 
tag were obtained by inserting into pCDNA3 vector (Invitrogen) HA-
tagged versions of human SEPT2, SEPT6, SEPT7, SEPT9, or SEPT11. 
These plasmids were then used to generate expression vectors for KRn 
septin mutants (in which all lysines from the N-terminal domain were 
replaced by arginines), KRn+m septin mutants (in which all lysines 
from the N-terminal and central domains were replaced by arginines), 
or KRc septin mutants (in which all lysines from the C-terminal do-
main were replaced by arginines). Plasmids encoding septins fused to 
Figure 8. SUMO-deficient septin bundles localize at intercellular bridges 
during cell division. (a) Fluorescent light microscopy images of HeLa cells 
transfected with HA-tagged WT, non-SUMOylatable (KRc), or constitutively 
SUMOylated (KRcSUMO1) SEPT7. Cells were stained for HA-tagged septins 
(anti-HA antibodies, green) and KIF20A to label intercellular midbodies 
(red). Bars, 2 µm. (b) Percentage of transfected cells undergoing cell divi-
sion and showing septin recruitment or septin bundles longer than 5 µm 
and thicker than 1 μm at intercellular midbodies (mean from three indepen-
dent experiments; error bars, SD; **, P < 0.01).
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SUMO1 or SUMO2 were obtained by inserting at the C terminus of 
the corresponding HA-tagged septin the sequence of human mature 
SUMO1 or SUMO2, deleted for their C-terminal diglycine motifs to 
avoid aberrant covalent linkage to other cellular proteins. All generated 
constructs were verified by sequencing.
Antibodies
Primary antibodies used for immunoblot analysis and immunofluores-
cence are described in Table S3. Rabbit polyclonal antibodies against 
Ubc9 (R202) was obtained in-house by immunizing rabbits with re-
combinant proteins produced in Escherichia coli. Antibodies against 
SEPT6 (R136) and SEPT11 (R174) were obtained by immunizing 
rabbits with synthetic peptides (CLL QSQ GSQ AGG SQT LKR DK and 
CGV QIY QFP TDE ETV AEI for SEPT6 and SEPT11, respectively). All 
rabbit immune sera were further purified by affinity with the corre-
sponding recombinant protein or synthetic peptides.
Cell culture and transfections
HeLa cells (CCL-2; ATCC) were cultivated in MEM-glutamax medium 
(Life Technologies) supplemented with 10% fetal calf serum, MEM 
nonessential amino acids (Life Technologies), and 1  mM sodium 
pyruvate (Life Technologies). U-2 OS cells (HTB-96; ATCC) were 
cultivated in McCoy’s 5A modified medium (Life Technologies) sup-
plemented with 10% fetal calf serum. For immunofluorescence anal-
yses, HeLa and U-2 OS cells were seeded at a density of 0.5 × 105 
and 1.0 × 105 cells on 4-cm2 glass coverslips, respectively. HeLa and 
U-2 OS cells were then transfected the day after with 1.5 µg and 0.75 
µg DNA, respectively, using Lipofectamine LTX reagents (Invitrogen) 
and processed for immunofluorescence analysis 72 h after transfection. 
For cotransfection in HeLa cells, plasmids were added at a 1:1 ratio. 
For video microscopy, HeLa cells were seeded at a density of 0.4 × 
105 cells in 35-mm Petri dishes with coverglass (Mattek Corporation). 
The day after, cells were transfected with 500 ng GFP-SEPT11 expres-
sion vectors or cotransfected with 80 ng pEGFP-N2 plasmid (Clontech) 
and 420 ng SEPT7 expression vectors using Lipofectamine LTX re-
agents. For analysis of septin expression levels, 1.25 × 105 HeLa cells 
were seeded in 4-cm2 wells, transfected the day after as previously 
described, and then directly lysed 48 h after transfection in Laemmli 
buffer (0.125 M Tris, pH 6.8, 4% SDS, 20% glycerol, and 100 mM 
DTT). For His pull-down and immunoprecipitation assays, 2.3 × 106 
HeLa cells were seeded in 75-cm2 flasks and transfected the day after 
with 27 µg of plasmids using Lipofectamine LTX reagents. Cells were 
then lysed and used for His pull-down or immunoprecipitation assays.
Cell synchronization
HeLa cells were grown in 75-cm2 flasks to 40% confluency and blocked 
for 16 h in culture medium supplemented with 2.5 mM thymidine (Sig-
ma-Aldrich). Cells were then washed four times in PBS, grown in me-
dium supplemented with 24  µM deoxycytidine (Sigma-Aldrich) for 
1 h, and transfected for 4 h with His6-SUMO1 expression vector. After 
transfection, cells were incubated for an additional 3 h in culture me-
dium supplemented with 24 µM deoxycytidine-containing medium and 
then blocked again in medium supplemented with 2.5 mM thymidine 
for 16 h. Cells were finally released from the second thymidine block 
by extensive washes in PBS and incubated in cell culture medium sup-
plemented with 24 µM deoxycytidine.
His pull-down assays
SUMOylated proteins from cell lysates were isolated as described in 
Tatham et al. (2009). HeLa cells transfected with His6-SUMO expres-
sion vectors were washed in PBS and lysed in lysis buffer (6 M guan-
idium-HCl, 10 mM Tris, 100 mM sodium phosphate buffer, pH 8.0, 
5 mM β-mercaptoethanol, and 5 mM imidazole). Nickel–nitrilotriacetic 
acid agarose resin (Qiagen) prewashed in lysis buffer was incubated 
with cell lysates overnight at 4°C. Resin was then washed once in lysis 
buffer, once in wash buffer, pH 8.0 (8 M urea, 10 mM Tris, 100 mM 
sodium phosphate buffer, pH 8.0, 0.1% Triton X-100, and 5 mM β-mer-
captoethanol), and three times in wash buffer, pH 6.3 (8 M urea, 10 mM 
Tris, 100 mM sodium phosphate buffer, pH 6.3, 0.1% Triton X-100, 
5 mM β-mercaptoethanol, and 10 mM imidazole). SUMOylated pro-
teins were then eluted from the resin using elution buffer (200 mM im-
idazole, 5% SDS, 150 mM Tris-HCl, pH 6.8, 30% glycerol, 720 mM 
β-mercaptoethanol, and 0.0025% bromophenol blue).
Immunoprecipitations
Transfected HeLa cells were rinsed three times in cold PBS. For im-
munoprecipitation of FLAG-Ubc9, cells were lysed for 20 min in 
modified RIPA buffer (50  mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% 
sodium-deoxycholate, 150 mM NaCl, 1 mM EDTA, 20 mM N-ethyl-
maleimide, and complete protease inhibitor cocktail [Roche]). For im-
munoprecipitation of HA-tagged septins, cells were lysed for 20 min 
in septin lysis buffer (20 mM Tris, pH 8.0, 1% NP-40, 150 mM NaCl, 
10% glycerol, 20 mM N-ethylmaleimide, complete protease inhibitor 
cocktail [Roche], and PhosSTOP phosphatase inhibitors [Sigma-Al-
drich]). Lysates were centrifuged for 15 min at 4°C at 16,000 g, and 
supernatants were incubated for 15 min with protein G–Sepharose 
beads (GE Healthcare) to eliminate unspecific binding of proteins to 
beads. After the removal of the beads, cleared lysates were then in-
cubated overnight at 4°C with anti-FLAG (M2; Sigma-Aldrich) or 
anti-HA (6E2; Cell Signaling Technologies) antibodies. The immu-
nocomplexes were then captured by incubating samples for 3 h with 
protein G–Sepharose beads. Beads were finally collected and washed 
four times in the corresponding lysis buffer. For FLAG immunoprecip-
itation, captured proteins were eluted using 3× FLAG peptide (100 µg/
ml of 3× FLAG peptide [Sigma-Aldrich] in 50 mM Tris-HCl, pH 7.4, 
and 150 mM NaCl). For HA immunoprecipitation, captured proteins 
were eluted using Laemmli buffer.
Immunoblotting
Cells lysed in Laemmli buffer and proteins eluted from His pull-down 
or immunoprecipitation assays were separated on SDS-polyacrylamide 
gels. Proteins were transferred to polyvinylidene fluoride membranes 
and incubated with primary antibodies (see Table S3 for primary anti-
body information). Membranes were then incubated with anti–mouse 
and anti–rabbit HRP-conjugated antibodies (AbCys). Proteins were 
revealed using Pierce ECL 2 Western blotting substrate (Fisher Sci-
entific). All displayed immunoblots are representative of at least two 
independent experiments.
Immunofluorescence
HeLa and U-2 OS cells on coverslips were fixed for either 20 min in 
PBS + 4% paraformaldehyde, followed by a 15-min step of permeabi-
lization in PBS + 0.3% Triton X-100, or fixed for 15 min in ice-cold 
methanol at −20°C. Cells were then incubated for 3 h with primary an-
tibodies (see Table S3 for primary antibody information) in PBS + 1% 
BSA, washed, and incubated for 1 h with Alexa Fluor 488– or 546–con-
jugated anti–mouse and anti–rabbit secondary antibodies (Molecular 
Probes) in PBS + 1% BSA. F-actin was stained with Alexa Fluor 647–
phalloidin (Molecular Probes) and DNA with DAPI. Glass coverslips 
were finally washed and mounted using Fluoromount (Interchim). Cells 
were imaged at room temperature using a 200 M inverted microscope 
(Axiovert; Zeiss) equipped with 100× 1.3 NA NeoFLU AR, 63× 1.4 
NA Plan-Apochromat, or 40× 1.3 NA Plan-Apochromat Plan-Neofluar 
objectives and a camera (Neo sCMOS; Andor) and was controlled by 
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Metamorph software (Universal Imaging). Quantification of aberrant 
septin bundles and multinucleated cells was performed by analyzing at 
least 100 transfected cells from 15 independent fields per condition and 
per experiment (three to five independent experiments). For characteri-
zation of septin filaments in cell bridges during cytokinesis, at least 25 
transfected cells undergoing cell division were analyzed per condition 
and per experiment (three independent experiments). P-values were cal-
culated using a two-tailed two-sample equal-variance Student’s t test.
Videomicroscopy and FRAP experiments
For time-lapse phase-contrast microscopy, HeLa cells cotransfected 
with expression vectors for GFP and SEPT7 were imaged in HeLa 
cells culture medium in an open chamber (Life Imaging) equilibrated in 
5% CO2 and maintained at 37°C. Time-lapse sequences were recorded 
every 10 min for 48 h using an inverted microscope (Eclipse Ti; Nikon) 
equipped with a 20× 0.45 NA Plan FluorELWD objective and a camera 
(CoolSNAP HQ2; Photometrics) and was controlled by Metamorph 
software. Analyses were performed on at least 50 transfected cells (i.e., 
GFP-positive cells) per condition and per experiment (three indepen-
dent experiments). For FRAP experiments, HeLa cells transfected with 
expression vector for WT or non-SUMOylatable GFP-SEPT11 were 
imaged in phenol red–free FluoroBrite DMEM (Life Technologies) in 
an open chamber equilibrated in 5% CO2 and maintained at 37°C. Im-
ages were acquired using an inverted microscope (Axio Observer.Z1; 
Zeiss) equipped with a 100× 1.4 NA Plan-Apochromat objective and a 
camera (Evolve; Photometrics) and was controlled by Metamorph soft-
ware. Square areas of 60 µm2 containing GFP-tagged septin filaments 
were bleached using an iLas2 system (Roper Scientific) with a sequence 
of 25 irradiations at 100% laser intensity. Equivalent laser intensity, 
repetition, and exposure time were used for each measurement. Images 
were taken 20 s before photobleaching and 6 min after photobleaching 
at a rate of 4 s per frame. Fluorescence intensities were quantified after 
background subtraction and normalization against unbleached areas 
using Metamorph software.
Phylogenetic analyses
Sequences of septins were aligned using CLU STA LW2 with default 
parameters. The corresponding phylogenetic tree was obtained using 
the neighbor-joining method and rooted using yeast Cdc3 septin as an 
outgroup. For each septin, one isoform from the UniProt databank was 
selected: SEPT1, isoform 1 (Q8WYJ6-1); SEPT2, isoform 1 (Q15019-
1); SEPT3, isoform 1 (Q9UH03-1); SEPT4, isoform 1 (O43236-1); 
SEPT5, isoform 1 (Q99719-1); SEPT6, isoform II (Q14141-1); SEPT7, 
isoform 1 (Q16181-1); SEPT8, isoform 1 (Q92599-1); SEPT9, isoform 
1 (Q9UHD8-1); SEPT10, isoform 1 (Q9P0V9-1); SEPT11, isoform 1 
(Q9NVA2-1); SEPT12, isoform 1 (Q8IYM1-1); SEPT14 (Q6ZU15); 
and yeast septin Cdc3 (P32457).
Online supplemental material
Fig. S1 describes the assay used to detect protein SUMOylation. Fig. 
S2 shows that non-SUMOylatable septins colocalize with endogenous 
SEPT2, but not with actin filaments in HeLa cells. Fig. S3 shows that 
non-SUMOylatable septins colocalize with endogenous SEPT9, but 
not with actin filaments in HeLa cells. Fig. S4 shows that non-SUMOy-
latable septin variants coimmunoprecipitate with endogenous septins 
and that expression of these non-SUMOylatable septin variants does 
not alter endogenous septin protein levels. Fig. S5 shows that non-SU-
MOylatable SEPT7 and SEPT11 induce defects in septin bundle forma-
tion and cell division both in HeLa and U-2 OS cells. Table S1 shows 
that human septins lack canonical SIMs. Table S2 provides information 
on the plasmids used in this study. Table S3 provides information on the 
antibodies used in this study.
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